🔴 Nautilus Biotechnology is trading 5.6% down in pre-market with no identified company-specific catalyst

Nautilus Biotechnology is trading at $3.06, down 5.56% in pre-market, with no new company announcement identified to explain the decline.

• Q3 2026 results are scheduled before market open on October 27, a known upcoming event rather than a newly reported catalyst.
• Commentary on the prior rally cited sector momentum and earnings anticipation but does not establish a cause for the decline.
• Major indices are mixed in the supplied market context, so broad-market direction does not clearly explain the move.